Keyphrases
COVID-19
100%
Randomized Evaluation
100%
COVID-19 Treatment
100%
Platform Trials
100%
Tocilizumab
100%
Hypoxia
37%
Systemic Inflammation
37%
Systemic Corticosteroids
37%
Standard of Care
25%
Rate Ratio
25%
Invasive Mechanical Ventilation
25%
Clinical Outcomes
12%
Usual Care
12%
Trial Participants
12%
C-reactive Protein
12%
Intention-to-treat
12%
Adult Patients
12%
Risk Ratio
12%
Composite Endpoint
12%
Patient Condition
12%
Improved Survival
12%
Random Assignment
12%
Possible Treatments
12%
Oxygen Saturation
12%
Respiratory Support
12%
Second Dose
12%
Oxygen Therapy
12%
28-day Mortality
12%
Hospitalized COVID-19 Patients
12%
Medicine and Dentistry
COVID-19
100%
COVID-19 Therapy
100%
Tocilizumab
100%
Hypoxia
37%
Corticosteroid
37%
Artificial Respiration
25%
Intention-to-Treat Analysis
12%
C Reactive Protein
12%
Oxygen Saturation
12%
Oxygen Therapy
12%
Assisted Ventilation
12%
Immunology and Microbiology
COVID-19
100%
Tocilizumab
100%
Systemic Inflammation
37%
C-Reactive Protein
12%
Oxygen Saturation
12%
Pharmacology, Toxicology and Pharmaceutical Science
Tocilizumab
100%
Hypoxia
37%
Inflammation
37%
Corticosteroid
37%
C Reactive Protein
12%